| |
| |
| Preface | |
| |
| |
| List of Contributors | |
| |
| |
| |
| Macro-anatomy of the prostate | |
| |
| |
| |
| |
| Embryology and development of the prostate | |
| |
| |
| |
| |
| Molecular control of prostate growth | |
| |
| |
| |
| |
| Stromal-epithelial interactions: molecular aspects and relevance to benign prostatic hyperplasia | |
| |
| |
| |
| |
| Prostatic adrenoceptors | |
| |
| |
| |
| |
| 5 Alpha-reductase in prostate disease | |
| |
| |
| |
| |
| Pathology of benign prostatic hyperplasia | |
| |
| |
| |
| |
| Bladder responses to obstruction | |
| |
| |
| |
| |
| Molecular genetics of benign prostatic hyperplasia | |
| |
| |
| |
| |
| Population-based studies of benign prostatic hyperplasia | |
| |
| |
| |
| |
| Natural history of benign prostatic hyperplasia | |
| |
| |
| |
| |
| Evaluating symptoms and functional status | |
| |
| |
| |
| |
| Clinical assessment: digital rectal examination | |
| |
| |
| |
| |
| Prostate specific antigen and cancer assessment | |
| |
| |
| |
| |
| Flow rate and post-void residual issues | |
| |
| |
| |
| |
| Urodynamics and benign prostatic hyperplasia | |
| |
| |
| |
| |
| Imaging and benign prostatic hyperplasia | |
| |
| |
| |
| |
| The role and interpretation of core biopsies in clinical benign prostatic hyperplasia | |
| |
| |
| |
| |
| Neurological and neurophysiological assessment | |
| |
| |
| |
| |
| Watchful waiting | |
| |
| |
| |
| |
| The placebo effect in the treatment of benign prostatic hyperplasia | |
| |
| |
| |
| |
| Finasteride therapy for benign prostatic hyperplasia | |
| |
| |
| |
| |
| Epristeride: a new 5 alpha-reductase inhibitor for the treatment of benign prostatic hyperplasia | |
| |
| |
| |
| |
| Other hormonal treatments | |
| |
| |
| |
| |
| Terazosin for the treatment of benign prostatic hyperplasia | |
| |
| |
| |
| |
| Doxazosin in the treatment of obstruction of the lower urinary tract | |
| |
| |
| |
| |
| Alfuzosin | |
| |
| |
| |
| |
| Tamsulosin | |
| |
| |
| |
| |
| Combination therapies for benign hyperplasia | |
| |
| |
| |
| |
| Phytotherapeutic agents | |
| |
| |
| |
| |
| Standard surgical interventions: TUIP/TURP/OPSU | |
| |
| |
| |
| |
| Laser prostatectomy | |
| |
| |
| |
| |
| Interstitial laser coagulation | |
| |
| |
| |
| |
| Hyperthermia treatment for benign prostatic hyperplasia | |
| |
| |
| |
| |
| Transurethral thermotherapy | |
| |
| |
| |
| |
| Transurethral needle ablation of the prostate | |
| |
| |
| |
| |
| High-intensity focused ultrasound | |
| |
| |
| |
| |
| Transurethral balloon dilation of the prostate | |
| |
| |
| |
| |
| Temporary stents | |
| |
| |
| |
| |
| Prostatic endoprosthetics | |
| |
| |
| |
| |
| Transurethral electro-vaporization of the prostate | |
| |
| |
| |
| |
| Treatment outcomes and their interpretation in benign prostatic hyperplasia | |
| |
| |
| |
| |
| Guidelines for diagnosis and management of benign prostatic hyperplasia | |
| |
| |
| |
| |
| Economics of benign prostatic hyperplasia | |
| |
| |
| |
| |
| Shared care for benign prostatic hyperplasia | |
| |
| |
| |
| |
| Prostate diseases beyond the year 2000: present and future burden of prostate diseases | |
| |
| |
| |
| Index | |